openPR Logo
Press release

Fabry Disease Treatment Market Business Opportunities with Top Players Amicus Therapeutics, Sanofi Genzyme, Idorsia, Protalix BioTherapeutics

07-15-2019 08:17 AM CET | Health & Medicine

Press release from: Coherent Market Insights

Fabry Disease Treatment

Fabry Disease Treatment

Fabry disease also called as Anderson-Fabry disease and alpha-galactosidase-A deficiency is an X-linked, hereditary, lysosomal storage disease caused due to paucity of an enzyme α galactosidase A (an enzyme required to metabolize lipids, fat-like substances that include oils, waxes, and fatty acids). The mutated gene leads the formation of lipids to harmful levels in various part of body such as the autonomic nervous system, cardiovascular system, eyes, and kidneys. Some of the common symptoms of this multisystem disorder include chronic pain, acroparesthesia, gastrointestinal disturbances, characteristic skin lesions (angiokeratomata), progressive renal impairment, cardiomyopathy, and stroke.

Fabry Disease Treatment Market Drivers

In recent past, various regulatory bodies of key regions have approved novel medications for treatment of Fabry disease. Approval and launch of such novel medications in the region is expected to significantly support global Fabry disease treatment market growth over the forecast period.

For instance, in August 2018, Amicus Therapeutics, Inc., received the U.S. Food and Drug Administration (FDA) approval for its drug Galafold (migalastat). It is the first oral medication indicated for the treatment of adults with Fabry disease.

The presence of robust medication pipeline indicated for treatment of Fabry disease is also expected to be a major factor fueling growth of global Fabry disease treatment market over the forecast period. Table mentioned below represents list of some novel therapies in pipeline for Fabry disease treatment.

Request A Sample Copy:
https://www.coherentmarketinsights.com/insight/request-sample/2326

Furthermore, key players in the market are majorly investing in development of novel therapies for Fabry disease treatment, such strategic funding’s by various players is expected to drastically fuel global Fabry Disease treatment market growth over the forecast period. For instance, in February 2018, AvroBio Inc., closed US$ 60 million financing to support the phase 2 study of its novel gene therapy, AVR-RD-01 underdevelopment for the treatment of Fabry disease.

Fabry Disease Treatment Market Regional Analysis

Europe Fabry disease treatment market is expected to witness a drastic growth over the forecast period, owing to penetration of key players in key regions of Europe with their novel products for Fabry disease. For instance, Amicus Therapeutics Inc. launched Galafold (Migalastat) for treatment of Fabry disease in Italy (in March 2017) and in Spain (in January 2018)

In November 2018, JCR Pharmaceuticals Co., Ltd, a Japan-based company launched biosimilar for agalsidase beta for treatment of Fabry disease. Launch of biosimilars is expected to increase affordability of these therapies in key regions of Asia Pacific as biosimilars are quite cheaper than biologics, hence it is expected to boost Asia Pacific Fabry disease treatment market growth.

Fabry Disease Treatment Market Restraint

Fabry disease is a very rare disease affecting around 1 individual in 50,000 (according to the National Fabry Disease Foundation), the diagnosis of Fabry disease is confirmed by demonstrating an enzyme deficiency in males and by identifying the specific GLA gene mutation in males and females.

Hence, low diagnostic rate due to unavailability of such diagnostic procedures and trained professionals in emerging economies such as Africa, India, and China are expected to be major factor restraining global Fabry disease treatment market growth.

Fabry Disease Treatment Market Key Players

Key players operating in global Fabry disease treatment market include: Amicus Therapeutics Inc., Sanofi Genzyme (Sanofi S.A. company), Idorsia Pharmaceuticals Ltd., Protalix BioTherapeutics, Inc., AvroBio Inc., JCR Pharmaceuticals Co., Ltd., Resverlogix Corp, and Ozmosis Research Inc.

Get PDF Brochure of This Business Report:
https://www.coherentmarketinsights.com/insight/request-pdf/2326

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fabry Disease Treatment Market Business Opportunities with Top Players Amicus Therapeutics, Sanofi Genzyme, Idorsia, Protalix BioTherapeutics here

News-ID: 1803684 • Views: 2658

More Releases from Coherent Market Insights

Portering Chair Market Revenue by Top Players Accora Ltd, Antano Group, Bristol …
Increasing medical casualties due to growing health problems such as heart attacks, breathing disorders coupled with other elderly related health conditions and rising incidences of trauma cases are the major factors driving the global portering chair market growth. According to the Centers for Disease Control and Prevention (CDC), around 2.5 million people were hospitalized in the U.S. in 2014, due to accident injuries that indicated high risk of bone damage. Furthermore,
Virtual Rehabilitation and Telerehabilitation System Market 2020 Revenue Opportu …
Virtual rehabilitation and telerehabilitation system is an equipment used for treatment in substance abuse, and application in educational services and mental health programs. Telerehabilitation services help medical professionals to analyze, supervise, consult, and diagnose diseases. Telerehabilitation services can be provided by healthcare service providers in medical branches such as physiotherapy. Increasing cases of disability among the population is expected to boost demand for virtual rehabilitation and telerehabilitation system, thereby driving growth
Needle-free IV Connectors Market 2020 – Insights by Top Players Baxter Interna …
The Needle-free IV Connectors Market report offers historical and forecast market data, demand, application details, price trends, and company shares of the leading Needle-free IV Connectors Market by geography. Market report studies the global market, analyzes and researches the Needle-free IV Connectors status and forecast in United States, Latin America, Europe, Japan, Asia Pacific, China, India and Southeast Asia. The report splits the market size, by volume and value, on
Electric Wheelchair Market 2020 Industry Analysis by Top Players Invacare Corpor …
The Electric Wheelchair Market report offers historical and forecast market data, demand, application details, price trends, and company shares of the leading Electric Wheelchair Market by geography. Market report studies the global market, analyzes and researches the Electric Wheelchair status and forecast in United States, Latin America, Europe, Japan, Asia Pacific, China, India and Southeast Asia. The report splits the market size, by volume and value, on the basis of

All 5 Releases


More Releases for Fabry

Fabry Disease Market to Exhibit Impressive Growth During 2016-2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Fabry Disease Market to Reflect Impressive Expansion During 2016-2026
Fabry diseaseis also known as Anderson-Fabry disease and alpha-galactosidase A deficiency. It is a rare genetic disorder of lipid metabolism resulting from the deficient activity of the alpha-galactosidase A (a-Gal A) enzyme. The deficiency of the enzyme is caused by the alterations in the genes that instructs the cells to make alpha-galactosidase A (a-Gal A) enzyme. Fabry disease is known to cause variety of systemic symptoms and complications, one of
Fabry Disease - Pipeline Review, H2 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H2 201 to its growing collection of premium market research reports. Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H2 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called
Fabry Disease Therapeutic Market Geographical Analysis And Forecast To 2022
Report Bazzar has released its latest research-based report entitled ‘Fabry Disease Therapeutic market.' This comprehensive report provides a holistic approach to the market growth with a detailed and precise analysis of the overall competitive scenario of the Fabry Disease Therapeutic Market worldwide along with the key trends and latest technologies, playing a prominent role in the Fabry Disease Therapeutic market growth over the predicted period. It also takes into account
Fabry Disease Market | Analysis & Key Trends 2023
Fabry disease is an unusual, life-threatening situation with debilitating condition. Fabry disease is an uncommon X-linked inherited disorder. It is caused by the lack of the enzyme alpha galactosidase-A (a-GAL A). It is initiated by the absence of enzyme required to metabolize the lipids, fat-like substances like waxes, oils, and fatty acids. This disease is also known as alpha-galactosidase-A deficiency. Often there is a complete deficiency of a-Gal results in
Fabry Disease - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Fabry Disease - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fabry Disease - Pipeline Review, H1 2017, provides an overview of the Fabry Disease (Genetic Disorders) pipeline landscape. Fabry disease is an inherited disorder. Fabry disease results from abnormal deposits of a particular fatty substance (called